Bayer Acquires Perfuse in $2.45 Billion Deal episode artwork

EPISODE · May 6, 2026 · 6 MIN

Bayer Acquires Perfuse in $2.45 Billion Deal

from Eyewire News: The Podcast · host Eyewire News

Bayer expands ophthalmology pipeline with acquisiton of Perfuse Therapeutics; Viridian announces new phase 3 data for its investigational subcutaneous injection for chronic thyroid eye disease; and Steven Dell, MD discusses the impact of declining reimbursement could on ophthalmic practices. Learn more about your ad choices. Visit megaphone.fm/adchoices

NOW PLAYING

Bayer Acquires Perfuse in $2.45 Billion Deal

0:00 6:50

No transcript for this episode yet

We transcribe on demand. Request one and we'll notify you when it's ready — usually under 10 minutes.

Frequently Asked Questions

How long is this episode of Eyewire News: The Podcast?

This episode is 6 minutes long.

When was this Eyewire News: The Podcast episode published?

This episode was published on May 6, 2026.

What is this episode about?

Bayer expands ophthalmology pipeline with acquisiton of Perfuse Therapeutics; Viridian announces new phase 3 data for its investigational subcutaneous injection for chronic thyroid eye disease; and Steven Dell, MD discusses the impact of declining...

Can I download this Eyewire News: The Podcast episode?

Yes, you can download this episode by clicking the download button on the episode player, or subscribe to the podcast in your preferred podcast app for automatic downloads.
URL copied to clipboard!